71 results on '"J. Veran"'
Search Results
2. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis
- Author
-
Elisabeth Jouve, Chloé Dumoulin, David Bocara, Audrey Cras, Olivier Boyer, Françoise Dignat-George, Julie Brunet, Ygal Benhamou, Isabelle Auquit-Auckbur, Cécile Philandrianos, Nicolas Schleinitz, Veronique Bourgarel, Dominique Casanova, Camille Giverne, Stéphanie Mallet, Rosanna Ferreira, Yves-Marie Pers, Aurélie Daumas, Brigitte Granel, Joseph Château, Florence Sabatier, Hervé Levesque, Maxime Abellan Lopez, Jérôme Larghero, Jean-Robert Harlé, Laurent Arnaud, Jeremy Magalon, Guy Magalon, J. Veran, Arnaud Hot, L. Giraudo, Alexandra Giuliani, Dominique Farge, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre d'Investigation Clinique [Hôpital de la Conception - APHM] (CIC), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Hôpital Nord [CHU - APHM], Assistance Publique - Hôpitaux de Marseille (APHM), CHU Rouen, Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Recherche clinique appliquée à l'hématologie (URP_3518), Université Paris Cité (UPCité), McGill University = Université McGill [Montréal, Canada], Service de Médecine Interne [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital privé Jean Mermoz [Lyon], Hôpital Edouard Herriot [CHU - HCL], and Hospices Civils de Lyon (HCL)
- Subjects
medicine.medical_specialty ,Population ,Adipose tissue ,Placebo ,Scleroderma ,law.invention ,Rheumatology ,Randomized controlled trial ,law ,Fibrosis ,Internal medicine ,CHFS ,medicine ,Humans ,Pharmacology (medical) ,education ,education.field_of_study ,Scleroderma, Systemic ,Stromal Vascular Fraction ,business.industry ,Stromal vascular fraction ,medicine.disease ,Hand ,Autologous adipose tissue-derived stromal vascular fraction ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Adipose Tissue ,Regenerative medicine ,Systemic sclerosis ,business ,Cochin Hand Function Scale - Abstract
Objective To assess the superiority of adipose tissue-derived stromal vascular fraction (AD-SVF) injection into the fingers vs placebo in reducing hand disability in systemic sclerosis (SSc) patients. Methods We performed a double-blind, multicentre, phase II trial from October 2015 to January 2018 in France. SSc patients with a Cochin Hand Function Scale (CHFS) ≥20/90 were randomized 1:1 to receive injection of AD-SVF or placebo. AD-SVF was obtained using the automated processing Celution 800/CRS system. The placebo was lactated Ringer’s solution. The primary efficacy end point was the change of the CHFS score from baseline to 3 months. Secondary efficacy endpoints included the CHFS score at 6 months, hand function, vasculopathy, hand pain, skin fibrosis, sensitivity of the finger pulps, Scleroderma Health Assessment Questionnaire, patients and physician satisfaction, and safety. Results Forty patients were randomized. The AD-SVF and placebo groups were comparable for age, sex ratio, disease duration, skin fibrosis of the hands and main cause of hand disability. After 3 months’ follow-up, hand function significantly improved in both groups with no between-group difference of CHFS (mean change of −9.2 [12.2] in the AD-SVF group vs −7.6 [13.2] in the placebo group). At 6 months, hand function improved in both groups. Conclusion This study showed an improvement of hand function in both groups over time, with no superiority of the AD-SVF. Considering the limits of this trial, studies on a larger population of patients with homogeneous phenotype and hand handicap should be encouraged to accurately assess the benefit of AD-SVF therapy. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT02558543. Registered on September 24, 2015.
- Published
- 2021
3. Collyres de sérum autologue : traitement à long-terme dans le syndrome sec oculaire
- Author
-
Jeremy Magalon, J. Veran, F. Sabatier, M. Lazaro, N. Stolowy, L. Hoffart, M. Beylerian, H. Beylerian, A. Darque, and Fanny Grimaud
- Subjects
0301 basic medicine ,Gynecology ,medicine.medical_specialty ,Long term treatment ,business.industry ,Sjögren syndrome ,medicine.disease ,Autologous serum ,03 medical and health sciences ,Ophthalmology ,030104 developmental biology ,0302 clinical medicine ,030221 ophthalmology & optometry ,medicine ,Tears ,business - Abstract
Resume Introduction La secheresse oculaire est une pathologie plurifactorielle de la surface oculaire dont la frequence elevee, le retentissement significatif sur la qualite de vie et sur la vision, ainsi que le cout financier, en font un veritable probleme de sante publique. Si le traitement des formes minimes a moderees est generalement simple et efficace, celui des formes severes est souvent decevant. L’utilisation de collyres a base de serum autologue (CSA) represente une alternative therapeutique envisageable pour les cas les plus severes. L’objectif de notre etude est d’evaluer l’efficacite du traitement par CSA a long-terme chez des patients presentant des syndromes secs isoles refractaires aux traitements conventionnels ou secondaires a d’autres pathologies generales telles que le syndrome de Gougerot-Sjogren et la maladie du greffon contre l’hote (GVH), ou a des pathologies oculaires telles que les keratites neurotrophiques, les brulures chimiques et les pemphigoides cicatricielles oculaires. Patients et methodes Il s’agit d’une etude observationnelle retrospective monocentrique menee sur 47 patients, soit 83 yeux traites par collyre de serum autologue a l’Assistance Publique-Hopitaux de Marseille entre avril 2014 et avril 2017 pour syndrome sec oculaire severe isole ou secondaire. Les symptomes subjectifs des patients (score ocular surface disease index [OSDI]), leur degre de satisfaction ainsi que les effets secondaires ont ete recueillis a l’aide de questionnaires. Le break up time (BUT) et le score de Schirmer ont ete notes. Une evaluation clinique fondee sur un test de coloration corneenne a la fluoresceine (score Oxford) est realisee avant le traitement par CSA a P0 puis selon 5 periodicites : P1 (entre 1 et 3 mois), P2 (3 et 9 mois), P3 (9 a 15 mois) et P4 (15 mois a 24 mois), P5 (> 24 mois). Resultats Sur les 83 yeux traites, l’âge moyen etait de 54,39 ans ± 21,56 dont 20 hommes (42,55 %) et 27 femmes (57,44 %), les indications de traitement comprenaient principalement 25,53 % de GVH, 21,27 % de syndromes secs oculaires severes primitifs et 19,14 % de syndrome de Goujerot-Sjogren primaire. Le suivi moyen a ete de 9,82 mois ± 15,50. La variation du score OSDI entre P0 et P1 montre une diminution de 19,32 points ± 29,37 (p Discussion Des analyses biologiques complementaires sur la composition des CSA sont en cours afin de mettre en evidence des facteurs predictifs d’efficacite. Ainsi, les patients non repondeurs au traitement par CSA pourraient repondre aux collyres de serum allogenique, fabriques a partir de sang peripherique preleve chez un donneur sain a partir de sang de cordon. Conclusion Sur cette premiere serie de 83 yeux traites par CSA, une efficacite clinique a ete notee chez la majorite des patients. Aucune complication infectieuse n’a ete rapportee et le taux de satisfaction a ete tres eleve.
- Published
- 2018
4. What About the Rheological Properties of PRP/Microfat Mixtures in Fat Grafting Procedure?
- Author
-
P Piccerelle, R Ghazouane, M Abellan, Mélanie Velier, C. Philandrianos, Baptiste Bertrand, Pauline François, Jeremy Magalon, J. Veran, and C Orneto
- Subjects
Graft Rejection ,medicine.medical_specialty ,Esthetics ,Dentistry ,Cosmetic Techniques ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Rheology ,medicine ,Fat grafting ,Humans ,Rejuvenation ,Hyaluronic Acid ,Surgery, Plastic ,Graft rejection ,Platelet-Rich Plasma ,business.industry ,Graft Survival ,Surgery.plastic ,Surgery ,Adipose Tissue ,030220 oncology & carcinogenesis ,Platelet-rich plasma ,Tissue and Organ Harvesting ,Female ,Graft survival ,business - Abstract
Fat grafting has emerged as a reference procedure in daily plastic surgery practice. Unpredictable fat resorption is the main clinical problem. For this purpose, the addition of PRP to enhance fat revascularization is now an easy and popular procedure. However, no consensus exists regarding the respective volume of fat and PRP used to obtain the ideal mixture. This study investigated the rheological properties of microfat mixed with different proportions of PRP. Results obtained were compared with commercialized hyaluronic acid fillers. Microfat and PRP preparations were performed using standardized techniques. Lipoaspirate residue and blood were obtained from six patients undergoing aesthetic facial microlipofilling. Elastic modulus G’ and tan δ (proportion of elasticity versus fluidity) were obtained for the following conditions: microfat alone and microfat mixed with 10, 30 or 50% of PRP. An expected decrease in elastic modulus was observed by adding increase volumes of PRP. Two groups of products with different rheological properties were considered based on statistical differences highlighted regarding the value of G’. Mean tan δ varied from 0.20 ± 0.04 (microfat alone) to 0.28 ± 0.08 (50% microfat/50% PRP). Microfat mixed with 10% of PRP presents consistency comparable to stiffer fillers, whereas microfat mixed with 30 or 50% corresponds to softer fillers. Rheological differences were highlighted given the proportion of PRP added to the microfat. Further studies assessing the impact of increased doses of platelets in microfat/PRP mixtures on clinical outcomes should also be investigated. Our findings will help clinicians to choose a mixture that meets their specific needs for a given indication. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- Published
- 2017
5. Médecine régénérative et arthrose du poignet : traitement par injection intra-articulaire d’un mélange de micrograisse autologue associée à du plasma autologue enrichi en plaquettes
- Author
-
Florence Sabatier, J. Veran, Charlotte Jaloux, D. Casanova, J. Eraud, Elisabeth Jouve, Aurélie Iniesta, Najib Kachouh, Alice Mayoly, and C. Curvale
- Subjects
Rehabilitation ,Orthopedics and Sports Medicine ,Surgery - Abstract
La prise en charge de l’arthrose du poignet resistante au traitement medical fait appel a des chirurgies enraidissantes et non conservatrices. L’injection intra-articulaire de micrograisse autologue associee a du plasma autologue enrichi en plaquettes (PRP) est une alternative therapeutique prometteuse dans la prise en charge de cette pathologie. L’etude AMIPREP est un essai de phase I-IIa, prospectif, monocentrique, non comparatif, realise en ouvert evaluant l’injection intra-articulaire de « micrograisse et PRP » dans le poignet arthrosique. Quatre millilitres de « micrograisse et PRP » sont injectes dans l’articulation radio-carpienne sous anesthesie locale. Le critere de jugement principal est la tolerance (survenue d’evenements indesirables jusqu’a un mois post-injection). L’EVA, les scores fonctionnels DASH et PRWE, la force et les amplitudes articulaires sont egalement evalues jusqu’a 12 mois de recul. La regeneration cartilagineuse est evaluee a 12 mois par la variation de la surface de section du cartilage mesuree sur une IRM 3 T haute resolution. Douze patients ont ete inclus et traites entre juin 2017 et fevrier 2018. Aucun evenement indesirable grave n’a ete recense au cours du suivi. A 1 an de recul, une diminution statistiquement significative de la douleur (EVA (j0) = 50 [49–90] vs EVA (M12) = 30 [0–50], p = 0,003) et des scores fonctionnels DASH (DASH (j0) = 42,5 [22,5–73,3] vs DASH (M12) = 23,3 [1,7–63,3], p = 0,001) et PRWE (PRWE (j0) = 60,3 [35,5–96] vs PRWE (M12) = 20 [0–73], p = 0,001) a ete observee, ainsi qu’une augmentation statistiquement significative de la force (Jamar (j0) = 24,8 [13–44,3] vs Jamar (M12) = 49,3 [26–59,3], p = 0,001). Aucune difference significative n’a pu etre mise en evidence sur les amplitudes articulaires et la variation de la surface de section du cartilage mesuree sur IRM 3 T. Le melange micrograisse et PRP constitue un tissu d’interposition physiologique de qualite entre les surfaces articulaires lesees. Il possede une capacite de regeneration cartilagineuse grâce aux cellules souches multipotentes contenues dans la micrograisse et aux facteurs de croissance contenus dans le PRP. L’injection intra-articulaire de « micrograisse et PRP » autologues est une procedure innovante, simple et peu invasive qui pourrait etre une alternative therapeutique aux chirurgies lourdes et non conservatrices dans la prise en charge de l’arthrose du poignet resistante au traitement medical.
- Published
- 2019
6. Réparer les nerfs périphériques lésés avec des greffes autologues de cellules souches olfactives nasales
- Author
-
M. Chammas, Régis Legré, Patrick Decherchi, J.P. Marie, Francois Feron, Jeremy Magalon, O. Boyer, J. Veran, C. Giverne, F. Sabatier, and G. Magalon
- Subjects
Rehabilitation ,Orthopedics and Sports Medicine ,Surgery - Abstract
Le consortium TOURNESOL, regroupant 11 equipes de chercheurs et de cliniciens de trois villes (Marseille, Montpellier et Rouen) et finance par la Fondation de l’Avenir, a pour mission de mener deux essais cliniques destines a reparer des nerfs peripheriques leses–nerfs facials et des membres – grâce a des greffes autologues de cellules souches nasales. Pourquoi la therapie cellulaire ? Environ 100 000 operations de reparation nerveuse sont realisees chaque annee aux Etats-Unis et en Europe. Elles representent 2,8 % des traumatismes et sont le plus souvent responsables d’une perte de fonction voire d’invalidite. Malgre des progres dans le delai de prise en charge et dans la qualite du geste technique chirurgical, il n’y a eu aucun progres majeur depuis une vingtaine d’annees. Une approche de therapie cellulaire pourrait limiter l’inflammation et ameliorer la croissance axonale. Pourquoi les cellules souches olfactives nasales ? Chez le mammifere adulte, y compris chez l’homme, la muqueuse olfactive est le seul tissu nerveux capable d’auto-renouvellement. La plasticite de ce tissu est en partie assuree par des cellules souches qui sont multipotentes. Comme demontre par plusieurs membres du consortium, elles peuvent donner naissance a des cellules neurales (neurones, astrocytes, oligodendrocytes, cellules de Schwann). Leur potentiel therapeutique a ete teste avec succes dans differents modeles animaux de paraplegie, de la maladie de Parkinson, de surdite et d’amnesie. Que disent les etudes menees chez le rat par le consortium. Deux etudes, menees en parallele sur le nerf facial et le nerf peronier ont permis de montrer que la greffe de cellules souches olfactives : ameliore la recuperation fonctionnelle de la mobilite faciale ; diminue les syncinesies œil-bouche ; accroit les capacites locomotrices ; ameliore le seuil tetanique, le temps de contraction et le taux de relaxation musculaire Les cellules souches olfactives, medicament de therapie innovante, agree par l’ANSM. Avant de mener les essais cliniques, il a ete necessaire de cultiver les cellules souches dans un laboratoire de therapie cellulaire, dans des conditions repondant aux normes europeennes. Les essais cliniques multicentriques porteront sur une premiere serie de 10 patients avec des lesions negligees des nerfs collateraux et de la branche sensitive du nerf radial avec une perte de substance. La periode d’evaluation post-greffe s’etalera sur 12 mois. La chirurgie regenerative va representer une revolution dans la reparation des membres. Et les nerfs peripheriques devraient en beneficier.
- Published
- 2018
7. [Treatment of wrinkles of the upper lip by emulsified fat or 'Nanofat': Biological and clinical study about 4 cases]
- Author
-
F, Mesguich Batel, B, Bertrand, J, Magalon, P, François, M, Velier, J, Veran, S, Mallet, E, Jouve, F, Sabatier, and D, Casanova
- Subjects
Treatment Outcome ,Adipose Tissue ,Injections, Intradermal ,Patient Satisfaction ,Photography ,Rhytidoplasty ,Humans ,Rejuvenation ,Female ,Middle Aged ,Lip ,Skin Aging - Abstract
Emulsified fat injection showed its interest in aesthetic facial surgery. The adipose tissue harvested is mechanically emulsified and filtered. The suspension obtained is injected into the dermis through small diameter needles (27 to 30 gauges). The objective of our study was to evaluate the biological composition of emulsified fat and its clinical effectiveness in the treatment of peri-oral wrinkles in 4 patients aged 50 to 59 years.Each patient received an intradermal injection of emulsified fat in the peri-oral wrinkles prepared from abdominal fat under local anesthesia. The cell viability, stromal vascular fraction (FVS) composition in emulsified fat and the adipocyte differentiation capacity of mesenchymal stem cells (MSC) were studied. The clinical results were evaluated by standardized photographs, 3D microphotography, confocal microscopy, and self-evaluation of patient satisfaction over a period of 4 months.The biological study of the emulsified fat found a lysis of all the adipocytes. The mean number of FVS cells was 126,330±2758 cells by cc of emulsified fat with preserved cell viability (85.1±6.84 %) and a good proportion of regeneratives cells (18.77±6.2 %). The clinical study found a tendency to decrease the volume of wrinkles on standardized photography and 3D microphotography no significative. Patients were satisfied with treatment with an average score of 7±1.15/10 to 4 months.Intradermal injection of emulsified fat seems to be an interesting treatment of face wrinkles. Our study has shown its safety, but additional studies seems necessary to confirm its clinical efficacy.
- Published
- 2017
8. [Autologous serum tears: Long-term treatment in dry eye syndrome]
- Author
-
M, Beylerian, M, Lazaro, J, Magalon, J, Veran, A, Darque, F, Grimaud, N, Stolowy, H, Beylerian, F, Sabatier, and L, Hoffart
- Subjects
Adult ,Aged, 80 and over ,Male ,Serum ,Preservation, Biological ,Graft vs Host Disease ,Middle Aged ,Severity of Illness Index ,Lubricant Eye Drops ,Sjogren's Syndrome ,Tears ,Humans ,Surface Tension ,Dry Eye Syndromes ,Female ,Fluorescein ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
Dry eye disease is a multifactorial pathology of the ocular surface. The high incidence of this pathology, as well as its significant impact on quality of life and vision and its financial cost, makes it a real public health problem. While the treatment of mild cases is generally simple and effective, treatment of severe forms is often disappointing. The use of autologous serum tears (AST) represents a therapeutic alternative for the most severe cases. The purpose of our study is to evaluate the efficacy of long-term AST treatment in patients with severe dry eye disease refractory to conventional treatment or secondary to systemic diseases such as Sjögren's syndrome or Graft versus Host disease (GVH), or ocular pathologies such as neurotrophic keratitis, chemical burns and ocular cicatricial pemphigoid.This is a monocentric retrospective observational study conducted on 47 patients, with 83 eyes treated with autologous serum eye drops for isolated or secondary dry eye disease at the Marseille Public Hospitals between April 2014 and April 2017. The patients' subjective symptoms (ocular surface disease index [OSDI] score), their degree of satisfaction and the side effects were collected using questionnaires. Tear Break Up Time (BUT) and Schirmer scores were noted. A clinical evaluation based on fluorescein staining (Oxford score) was carried out prior to treatment with AST at P0 followed by 5 periods: P1 (between 1 and 3 months), P2 (3 to 9 months), P3 (9 to 15 months), P4 (15 months to 24 months), and P5 (24 months).Out of the 83 eyes treated, the mean age was 54.39±21.56. There were 20 males (42.55 %) and 27 females (57.44 %); treatment indications consisted mainly of 25.53 % GVH, 21.27 % severe dry eye disease and 19.14 % Sjögren syndrome. The mean duration of follow-up was 9.82 months±15.50. The OSDI score decreased by 19.32 points±29.37 (P0.05) between P0 and P1 and by 23.06 points±18.41 (P0.05) between P0 and P4. The Oxford clinical score showed a significant decrease by the third month of treatment, between P0 and P2, by 1.32 points±1.76 (P0.05). The Schirmer test and the BUT also showed an improvement in dry eye symptoms over time with AST, significantly at P1 (P0.05).Complementary biological analyzes on the composition of AST are under way in order to identify predictive factors of effectiveness; patients not responding to AST treatment might respond to allogeneic serum from healthy donor cord blood.On this first series of 83 eyes treated with ASD, clinical efficacy was noted in most of the patients. No infectious complications were reported, and the satisfaction rate was very high.
- Published
- 2017
9. Characterization and Comparison of 5 Platelet-Rich Plasma Preparations in a Single-Donor Model
- Author
-
Florence Sabatier, Jeremy Magalon, J. Veran, Nicolas Serratrice, Olivier Bausset, Guy Magalon, Françoise Dignat-Georges, Houssein Aboudou, and L. Giraudo
- Subjects
Adult ,Male ,Vascular Endothelial Growth Factor A ,medicine.medical_treatment ,Enzyme-Linked Immunosorbent Assay ,Transforming Growth Factor beta1 ,Andrology ,Leukocyte Count ,Young Adult ,Epidermal growth factor ,White blood cell ,Leukocytes ,medicine ,Humans ,Orthopedics and Sports Medicine ,Platelet ,Platelet activation ,Whole blood ,Platelet-Derived Growth Factor ,Analysis of Variance ,Platelet Count ,Platelet-Rich Plasma ,business.industry ,Growth factor ,Middle Aged ,Flow Cytometry ,Platelet Activation ,Healthy Volunteers ,Red blood cell ,medicine.anatomical_structure ,Platelet-rich plasma ,Immunology ,Erythrocyte Count ,Intercellular Signaling Peptides and Proteins ,Female ,business - Abstract
Purpose The purpose of this study was to compare the biological characteristics of platelet-rich plasma (PRP) obtained from 4 medical devices and a preparation developed in our laboratory using a single-donor model. Methods Ten healthy persons donated blood that was processed to produce PRP by use of 4 commercial preparation systems and a protocol developed in our laboratory. Volumes and platelet, white blood cell (WBC), and red blood cell concentrations were recorded. The platelet activation status was assessed by flow cytometry. Enzyme-linked immunosorbent assay was used to determine the concentrations of vascular endothelial growth factor, platelet-derived growth factor AB, epidermal growth factor, and transforming growth factor β1. We calculated platelet capture efficiency, relative composition, and increase factors from whole blood in platelets and WBC, as well as platelet and growth factor (GF) doses, provided from each preparation. Results Leukocyte-rich PRP was obtained with RegenPRP (RegenLab, Le Mont-sur-Lausanne, Switzerland) and the Mini GPS III System (Biomet Biology, Warsaw, IN) and provides PRP with higher proportions of red blood cells, WBCs, and neutrophils than leukocyte-poor PRP obtained with the Selphyl System (Selphyl, Bethlehem, PA), Arthrex ACP (Arthrex, Naples, FL), and the preparation developed in our laboratory. The highest platelet and GF concentrations and doses were obtained with the Mini GPS III System and the preparation developed in our laboratory. Different centrifugation protocols did not show differences in the percentages of activated platelets. Finally, a positive correlation between platelet doses and all the GFs studied was found, whereas a positive correlation between WBC doses and GFs was found only for vascular endothelial growth factor and epidermal growth factor. Conclusions In a single-donor model, significant biological variations in PRP obtained from different preparation systems were highlighted. The observed differences suggest different results for treated tissue and could explain the large variability in the clinical benefit of PRP reported in the literature. Clinical Relevance Our findings will help clinicians to choose a system that meets their specific needs for a given indication.
- Published
- 2014
10. OP008 An innovative treatment for refractory perianal fistulas in Crohn's disease: local micro reinjection of autologous fat and adipose derived stromal vascular fraction
- Author
-
Mélanie Serrero, P. Orsoni, Jean-Charles Grimaud, C. Visee, F. Sabatier, C. Philandrianos, and J. Veran
- Subjects
Pathology ,medicine.medical_specialty ,Crohn's disease ,business.industry ,Angiogenesis ,Gastroenterology ,Soft tissue ,Adipose tissue ,General Medicine ,Stromal vascular fraction ,medicine.disease ,Crohn's Disease Activity Index ,03 medical and health sciences ,0302 clinical medicine ,Autologous fat ,Refractory ,030220 oncology & carcinogenesis ,medicine ,030211 gastroenterology & hepatology ,business - Published
- 2017
11. Effets de la microréinjection du tissu adipeux autologue dans le visage des patients atteints de sclérodermie systémique
- Author
-
Aurélie Daumas, Guy Magalon, J. Serratrice, B. Granel, D. Casanova, C. Serratrice, J.G. Fuzibet, R. Truillet, N. Sautereau, Elisabeth Jouve, J. Veran, and L. Swiader
- Subjects
Gastroenterology ,Internal Medicine - Abstract
Introduction Les manifestations bucco-faciales de la sclerodermie systemique concernent plus de 90 % des patients et sont responsables d’un handicap fonctionnel et esthetique important avec un retentissement non negligeable sur l’estime de soi. Ces manifestations variees comprennent la sclerose cutanee peri-orale, l’amincissement des levres, les raghades peribuccales, la limitation de l’ouverture buccale, le syndrome sec et le syndrome douloureux temporo-mandibulaire. Leur retentissement peut etre evalue avec le score Mouth Handicap in Systemic Sclerosis (MHISS). La greffe sous cutanee de tissu adipeux autologue est utilisee depuis plus d’un siecle en chirurgie plastique et reparatrice pour ses proprietes volumatrices et trophiques. Il s’agit d’un soin repertorie par l’Assurance maladie et dont l’efficacite a aussi ete mise en evidence dans des formes localisees de sclerodermie comme la sclerodermie lineaire « en coup de sabre » et les morphees. Le but de l’etude est de determiner les effets fonctionnels et esthetiques de la microreinjection de graisse autologue au niveau du visage de patients atteints de sclerodermie systemique. Materiels et methodes Cette etude monocentrique evalue une procedure de soins courants. Elle inclut 14 patients atteints de sclerodermie systemique ayant un score MHISS (0–48) superieur a 20, un score cutane de fibrose du visage (0–3) superieur ou egal a 1, une ouverture buccale inferieure a 55 millimetres, un IMC superieur a 17 et un souhait de beneficier d’un soin au niveau du visage. Les patients recevant un traitement anticoagulant, anti-agregant plaquettaire ou une corticotherapie superieure a 20 mg par jour ne sont pas inclus. L’autogreffe de tissu adipeux est une procedure peu invasive s’effectuant entierement sous anesthesie locale. Cinquante millilitres de tissu adipeux sont preleves par une technique de lipoaspiration douce au niveau des faces internes des genoux et/ou de l’abdomen, par une canule de 2 mm de diametre. Le prelevement est immediatement dirige vers une poche de filtration a usage unique (Puregraft®) qui purifie par dialyse la graisse de maniere sterile, sans centrifugation en 15 minutes. Dix a 25 millilitres de graisse purifiee sont reinjectes avec une canule de 0,8 mm de diametre en deux a quatre points peribuccaux. La tolerance et l’efficacite sont evaluees, en post-operatoire puis trois et six mois apres la chirurgie. L’objectif principal est l’amelioration du score MHISS a 6 mois de la greffe de tissu adipeux autologue. Des criteres secondaires evaluent l’effet de la procedure sur plusieurs parametres : la qualite de vie (SHAQ), les douleurs ressenties au visage (EVA 0-100), le syndrome sec (Xerostomia Inventory et test au sucre), la fibrose cutanee (score de Rodnan au visage, ouverture buccale et cutometrie) et les modifications du visage (photographies standard et 3D). Resultats Le resultat attendu est une amelioration du score MHISS d’au moins 5 points sur 48, six mois apres la chirurgie ainsi qu’un effet positif de la microreinjection de graisse sur la douleur, la fibrose, le syndrome sec et la qualite de vie. Conclusion Notre equipe a une grande experience de l’utilisation du tissu adipeux a des fins trophiques. La validation de l’efficacite/tolerance de cette procedure de soins courants peu invasive serait une avancee importante dans le traitement des manifestations buccofaciales et dans l’amelioration de la qualite de la vie des patients.
- Published
- 2014
12. A Comparative In Vitro and In Vivo Study of Osteogenicity by Using Two Biomaterials and Two Human Mesenchymal Stem Cell Subtypes
- Author
-
L. Fievet, N. Serratrice, B. Brulin, L. Giraudo, J. Véran, N. Degardin, F. Sabatier, F. Féron, and P. Layrolle
- Subjects
bone marrow ,nose ,human mesenchymal stem/stromal cells ,osteoinduction ,biomaterials ,biphasic calcium phosphate ,Biology (General) ,QH301-705.5 - Abstract
Background: Bone repair induced by stem cells and biomaterials may represent an alternative to autologous bone grafting. Mesenchymal stromal/stem cells (MSCs), easily accessible in every human, are prototypical cells that can be tested, alone or with a biomaterial, for creating new osteoblasts. The aim of this study was to compare the efficiency of two biomaterials—biphasic calcium phosphate (BCP) and bioactive glass (BG)—when loaded with either adult bone marrow mesenchymal stem cells (BMMSCs) or newborn nasal ecto-mesenchymal stem cells (NE-MSCs), the latter being collected for further repair of lip cleft-associated bone loss.Materials and Methods: BMMSCs were collected from two adults and NE-MSCs from two newborn infants. An in vitro study was performed in order to determine the best experimental conditions for adhesion, viability, proliferation and osteoblastic differentiation on BCP or BG granules. Bone-associated morphological changes and gene expression modifications were quantified using histological and molecular techniques. The in vivo study was based on the subcutaneous implantation in nude mice of the biomaterials, loaded or not with one of the two cell types. Eight weeks after, bone formation was assessed using histological and electron microscopy techniques.Results: Both cell types—BMMSC and NE-MSC—display the typical stem cell surface markers—CD73+, CD90+, CD105+, nestin - and exhibit the MSC-associated osteogenic, chondrogenic and adipogenic multipotency. NE-MSCs produce less collagen and alkaline phosphatase than BMMSCs. At the transcript level, NE-MSCs express more abundantly three genes coding for bone sialoprotein, osteocalcin and osteopontin while BMMSCs produce extra copies of RunX2. BMMSCs and NE-MSCs adhere and survive on BCP and BG. In vivo experiments reveal that bone formation is only observed with BMMSCs transplanted on BCP biomaterial.Conclusion: Although belonging to the same superfamily of mesenchymal stem cells, BMMSCs and NE-MSCs exhibit striking differences, in vitro and in vivo. For future clinical applications, the association of BMMSCs with BCP biomaterial seems to be the most promising.
- Published
- 2022
- Full Text
- View/download PDF
13. Évaluation à 1 an de l’injection sous-cutanée de la fraction vasculaire stromale autologue d’origine adipeuse au niveau des doigts chez les patients atteints de sclérodermie systémique
- Author
-
Aurélie Daumas, Guy Magalon, B. Granel, P. Guillaume-Jugnot, L. Swiader, J. Veran, J. Serratrice, Florence Sabatier, Françoise Dignat-George, Elisabeth Jouve, S. Mallet, and R. Truillet
- Subjects
Gastroenterology ,Internal Medicine - Abstract
Introduction L’atteinte des mains, quasi constante au cours de la sclerodermie systemique, est responsable d’une impotence fonctionnelle, de douleurs et d’une alteration de la qualite de vie. Ses mecanismes sont multiples : lesions microvasculaires, fibrose cutanee, calcinose et atteinte osteo-articulaire. Nous avons evalue l’effet a 1 an de l’injection de la fraction vasculaire stromale (FVS) d’origine adipeuse dans les doigts des 12 patientes du protocole Scleradec. Patients et methodes La FVS etait preparee au moyen du dispositif medical Celution ® 800/CRS (Cytori Therapeutics, Inc., Etats-Unis) selon un procede simple et automatise. Un prelevement de tissu adipeux par lipoaspiration sous anesthesie locale permettait d’obtenir 5 mL de FVS. Apres dilution, qualification et caracterisation du produit cellulaire dans une unite de therapie cellulaire, 1 mL etait reinjecte a l’aide d’une canule de 25 Gauge (0,5 mm) au niveau des zones laterales des articulations interphalangiennes proximales pour les doigts longs et metacarpophalangiennes pour le pouce, sous neuroleptanalgesie dans un delai inferieur a 3 h apres le prelevement du tissu adipeux. Les resultats a 6 mois ont montre un benefice significatif sur la qualite de vie, le score de la main de Cochin (CHFS), le syndrome de Raynaud, la douleur, la circonference des doigts et le score de suppression vasculaire (SSV) a la capillaroscopie. Les 12 patientes ont ensuite ete revues a 1 an par les memes praticiens, en aveugle des resultats anterieurs. L’analyse statistique a porte sur la comparaison avant-apres des principaux parametres quantitatifs evalues a l’etat basal (M0) et a 1 an (M12), par un test de Student apparie. Les resultats sont donnes en moyenne (± ET) et le seuil de significativite est fixe a 0,05. Resultats Les 12 patientes etaient caracterisees par un âge moyen de 56,0 ± 10,1 ans, une duree de la maladie (hors Raynaud) de 9,9 ± 7 ans (extremes : 2–24), 9 avaient une forme cutanee limitee et aucune n’avait des facteurs de risque cardiovasculaire. La qualite de vie, evaluee par le score de SHAQ (0 a 3), s’ameliorait avec un score de 1,4 ± 0,3 a M0 a 0,8 ± 0,7 a M12 ( p = 0,0023). La valeur du CHFS diminuait de 48,5 ± 10,8 a M0 a 24,3 ± 19,8 a M12 ( p p p = 0,052). Le score de Rodnan applique a la main (0–18) etait respectivement de 10,9 ± 4,9 et de 8,4 ± 5,5 a M0 et M12 ( p = 0,014). Le score de Rodnan global (0–51) passait de 13,9 ± 9,8 initialement a 9,5 ± 9,0 a M12 ( p = 0,001). Une amelioration significative de la force de l’avant-bras et de la main ainsi que de la force de la pince pouce-index etait observee. On notait une augmentation des distances inter commissurales. Le score de Kapandji (0–10), evaluant l’opposition du pouce, augmentait de facon significative a M12. La moyenne de la circonference des doigts ainsi que le SSV diminuaient de facon significative. Le nombre total d’ulceres digitaux a l’inclusion etait de 15 contre 9 a M12. Neuf patientes notaient une repousse plus rapide et une meilleure trophicite des ongles. A 1 an, 4 patientes se declaraient tres satisfaites de la procedure, 5 satisfaites et 3 peu satisfaites. Conclusion L’injection de FVS dans les doigts reste benefique a 1 an sur l’atteinte microvasculaire, l’œdeme et la fibrose avec un impact sur le handicap de la main, la douleur et la qualite de vie. Ces resultats preliminaires devront etre confirmes par une etude comparative contre placebo sur un plus grand nombre de patients. L’utilisation de la FVS du tissu adipeux semble une option therapeutique prometteuse dans l’atteinte des mains au cours de la sclerodermie systemique.
- Published
- 2014
14. 245 Urodynamic and histologic effects of autologous adipose derived stem cells endoscopically injected in a porcin model of intrinsic sphincter deficiency
- Author
-
Françoise Dignat-George, L. Giraudo, Guy Magalon, Romain Boissier, Eric Lechevallier, Jeremy Magalon, J. Veran, Laurent Arnaud, Stéphane Garcia, Florence Sabatier, Stéphane Berdah, Gilles Karsenty, and Sophie Giusiano
- Subjects
medicine.medical_specialty ,Pathology ,business.industry ,Urology ,Internal medicine ,Intrinsic sphincter deficiency ,medicine ,Adipose tissue ,business ,Gastroenterology - Published
- 2013
15. [Surgical treatment of the paralytic leprous foot. Apropos of 8 cases treated in New Caledonia]
- Author
-
J, Veran, R, Farruggia, and B, Paret
- Subjects
Adult ,Foot Diseases ,Male ,New Caledonia ,Foot ,Leprosy ,Humans ,Paralysis ,Postoperative Period - Published
- 1981
16. [Further observations on IMAO-serotonin interactions on the agitation induced by morphine in albino mice]
- Author
-
J, Mercier and J, Veran
- Subjects
Mice ,Serotonin ,Monoamine Oxidase Inhibitors ,Behavior, Animal ,Morphine ,Animals - Published
- 1966
17. [Pharmacodynamic study of an antispasmodic and tranquilizing combination recommended in the treatment of digestive ulcers]
- Author
-
J, Mercier, S, Dessaigne, M R, Gavend, P, Etzensperger, and J, Veran
- Subjects
Mice ,Peptic Ulcer ,Dogs ,Tranquilizing Agents ,Animals ,Parasympatholytics ,Rabbits ,Motor Activity ,Gastrointestinal Motility ,Digestive System ,Oxazoles ,Rats - Published
- 1967
18. [In the pursuit of misguided or lost doctors]
- Author
-
F, SALIERES, J L, BARRAULT, M, BESSY, P, DOMINIQUE, L, DURTAIN, P, GUTH, J, RIGAUX, J, VERAN, and G M, VILLENAVE
- Subjects
Physicians ,Humans ,Medicine - Published
- 1950
19. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients
- Author
-
Aurélie Daumas, Audrey Benyamine, Françoise Dignat-George, Florence Sabatier, Romain Truillet, Dominique Casanova, Guy Magalon, L. Giraudo, Brigitte Granel, Jeremy Magalon, J. Veran, Elisabeth Jouve, Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Vascular research center of Marseille (VRCM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), CIC-CPCET, Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service de Médecine Interne (MARSEILLE - Med Int), Assistance Publique - Hôpitaux de Marseille (APHM), Service de chirurgie de la main, chirurgie plastique et réparatrice des membres, and DIGNAT-GEORGE, Françoise
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,Activities of daily living ,Injections, Subcutaneous ,Adipose tissue ,Cell Fractionation ,Transplantation, Autologous ,General Biochemistry, Genetics and Molecular Biology ,Scleroderma ,Fingers ,03 medical and health sciences ,Subcutaneous injection ,0302 clinical medicine ,Fibrosis ,Skin Ulcer ,medicine ,Humans ,Patient Reported Outcome Measures ,Aged ,030203 arthritis & rheumatology ,Scleroderma, Systemic ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,Endothelial Cells ,Raynaud Disease ,General Medicine ,Stromal vascular fraction ,Middle Aged ,medicine.disease ,Hand ,3. Good health ,Surgery ,Clinical trial ,030104 developmental biology ,Treatment Outcome ,Adipose Tissue ,Female ,Stromal Cells ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Iloprost ,medicine.drug ,Follow-Up Studies - Abstract
International audience; Introduction: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived stromal vascular fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived stromal vascular fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial.Patients and method: Twelve females, mean age 54.5 ± 10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30 months after treatment.Results: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion.Conclusion: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived stromal vascular fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients.
20. Human nasal olfactory stem cells, purified as advanced therapy medicinal products, improve neuronal differentiation.
- Author
-
Jaloux C, Bonnet M, Vogtensperger M, Witters M, Veran J, Giraudo L, Sabatier F, Michel J, Legré R, Guiraudie-Capraz G, and Féron F
- Abstract
Background: Olfactory ecto-mesenchymal stem cells (OE-MSC) are mesenchymal stem cells derived from the lamina propria of the nasal mucosa. They display neurogenic and immunomodulatory properties and were shown to induce recovery in animal models of spinal cord trauma, hearing loss, Parkinsons's disease, amnesia, and peripheral nerve injury. As a step toward clinical practice, we sought to (i) devise a culture protocol that meets the requirements set by human health agencies and (ii) assess the efficacy of stem cells on neuron differentiation., Methods: Nasal olfactory mucosa biopsies from three donors were used to design and validate the good manufacturing process for purifying stem cells. All processes and procedures were performed by expert staff from the cell therapy laboratory of the public hospital of Marseille (AP-HM), according to aseptic handling manipulations. Premises, materials and air were kept clean at all times to avoid cross-contamination, accidents, or even fatalities. Purified stem cells were cultivated for 24 or 48 h and conditioned media were collected before being added to the culture medium of the neuroblastoma cell line Neuro2a., Results: Compared to the explant culture-based protocol, enzymatic digestion provides higher cell numbers more rapidly and is less prone to contamination. The use of platelet lysate in place of fetal calf serum is effective in promoting higher cell proliferation (the percentage of CFU-F progenitors is 15.5%), with the optimal percentage of platelet lysate being 10%. Cultured OE-MSCs do not show chromosomal rearrangement and, as expected, express the usual phenotypic markers of mesenchymal stem cells. When incorporated in standard culture medium, the conditioned medium of purified OE-MSCs promotes cell differentiation of Neuro2a neuroblastoma cells., Conclusion: We developed a safer and more efficient manufacturing process for clinical grade olfactory stem cells. With this protocol, human OE-MSCs will soon be used in a Phase I clinical based on their autologous transplantation in digital nerves with a neglected injury. However, further studies are required to unveil the underlying mechanisms of action., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Jaloux, Bonnet, Vogtensperger, Witters, Veran, Giraudo, Sabatier, Michel, Legré, Guiraudie-Capraz and Féron.)
- Published
- 2022
- Full Text
- View/download PDF
21. Intra Articular Injection of Autologous Microfat and Platelets-Rich Plasma in the Treatment of Wrist Osteoarthritis: A Pilot Study.
- Author
-
Mayoly A, Witters M, Jouve E, Bec C, Iniesta A, Kachouh N, Veran J, Grimaud F, Zavarro AC, Fernandez R, Bendahan D, Giraudo L, Dumoulin C, Chagnaud C, Casanova D, Sabatier F, Legré R, Jaloux C, and Magalon J
- Abstract
No injection treatment has been proven to be effective in wrist osteoarthritis. When conservative measures fail, its management involves invasive surgery. Emergence of biotherapies based on adipose derived stem cells (ADSC) offers promising treatments for chondral degenerative diseases. Microfat (MF) and platelets-rich plasma (PRP) mixture, rich in growth factors and ADSC could be a minimally invasive injectable option in the treatment of wrist osteoarthritis. The aim of this uncontrolled prospective study was to evaluate the safety of a 4 mL autologous MF-PRP intra-articular injection, performed under local anesthesia. The secondary purpose was to describe the clinical and MRI results at 12 months of follow-up. Patients' data collected were: occurrence of adverse effects, Visual analog scale (VAS), Disabilities of the Arm, Shoulder and Hand score (DASH) and Patient-Rated Wrist Evaluation (PRWE) scores, wrist strength, wrist range of motion and 5-level satisfaction scale. No serious adverse event was recorded. A statistically significant decrease in pain, DASH, PRWE and force was observed at each follow-up. Our preliminary results suggest that intra-articular autologous MF and PRP injection may be a new therapeutic strategy for wrist osteoarthritis resistant to medical symptomatic treatment prior to surgical interventions., Competing Interests: J.M. received honorarium for educational support from FIDIA, HORIBA ARTHREX and MACOPHARMA. These manufacturers had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Other authors did not declare any conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
22. Platelet-rich plasma preparations in sports rehabilitation: Where we started and where we should go.
- Author
-
Magalon J, Brandin T, Grimaud F, Rabarimeriarijaona S, Veran J, Dignat George F, and Sabatier F
- Subjects
- Humans, Platelet-Rich Plasma, Sports
- Published
- 2022
- Full Text
- View/download PDF
23. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis.
- Author
-
Daumas A, Magalon J, Jouve E, Casanova D, Philandrianos C, Abellan Lopez M, Mallet S, Veran J, Auquit-Auckbur I, Farge D, Levesque H, Benhamou Y, Arnaud L, Giraudo L, Dumoulin C, Giverne C, Boyer O, Giuliani A, Bourgarel V, Harlé JR, Schleinitz N, Brunet J, Pers YM, Ferreira R, Cras A, Boccara D, Larghero J, Château J, Hot A, Dignat-George F, Magalon G, Sabatier F, and Granel B
- Subjects
- Adipose Tissue, Fibrosis, Hand, Humans, Scleroderma, Systemic complications, Stromal Vascular Fraction
- Abstract
Objective: To assess the superiority of adipose tissue-derived stromal vascular fraction (AD-SVF) injection into the fingers vs placebo in reducing hand disability in systemic sclerosis (SSc) patients., Methods: We performed a double-blind, multicentre, phase II trial from October 2015 to January 2018 in France. SSc patients with a Cochin Hand Function Scale (CHFS) ≥20/90 were randomized 1:1 to receive injection of AD-SVF or placebo. AD-SVF was obtained using the automated processing Celution 800/CRS system. The placebo was lactated Ringer's solution. The primary efficacy end point was the change of the CHFS score from baseline to 3 months. Secondary efficacy endpoints included the CHFS score at 6 months, hand function, vasculopathy, hand pain, skin fibrosis, sensitivity of the finger pulps, Scleroderma Health Assessment Questionnaire, patients and physician satisfaction, and safety., Results: Forty patients were randomized. The AD-SVF and placebo groups were comparable for age, sex ratio, disease duration, skin fibrosis of the hands and main cause of hand disability. After 3 months' follow-up, hand function significantly improved in both groups with no between-group difference of CHFS (mean change of -9.2 [12.2] in the AD-SVF group vs -7.6 [13.2] in the placebo group). At 6 months, hand function improved in both groups., Conclusion: This study showed an improvement of hand function in both groups over time, with no superiority of the AD-SVF. Considering the limits of this trial, studies on a larger population of patients with homogeneous phenotype and hand handicap should be encouraged to accurately assess the benefit of AD-SVF therapy., Trial Registration: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02558543. Registered on September 24, 2015., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
24. Three-year outcome of local injection of autologous stromal vascular fraction cells and microfat in refractory perianal fistulas of Crohn's disease.
- Author
-
Guillo L, Grimaud F, Houser F, Prost C, Jouve E, Philandrianos C, Abellan M, Veran J, Visee C, Beyer-Berjot L, Desjeux A, Dignat-George F, Leone M, Grimaud JC, Sabatier F, Serrero M, and Magalon J
- Subjects
- Humans, Pilot Projects, Quality of Life, Retrospective Studies, Stromal Vascular Fraction, Treatment Outcome, Crohn Disease complications, Crohn Disease therapy, Mesenchymal Stem Cell Transplantation methods, Rectal Fistula etiology, Rectal Fistula therapy
- Abstract
Perianal fistulas in Crohn's disease are frequent and disabling, with a major impact on patients' quality of life. Cell-based therapy using mesenchymal stem cells represents new hope for these patients, but long-term efficacy remains challenging. In a pilot study, including patients with refractory complex perianal fistulas, autologous adipose-derived stromal vascular fraction (ADSVF) combined with microfat achieved combined remission in 60% of cases, with a good safety profile at 1 year. The purpose of this study is to assess whether these results were maintained at longer term. The safety and efficacy data of the ten patients were evaluated retrospectively 3 years after injection on the basis of clinical and radiological data. MRI were analysed according to the MAGNIFI-CD score. No adverse event was attributed to the experimental stem-cell treatment. Combined remission was achieved in 7 patients (70%) and associated with a significant improvement in the MAGNIFI-CD MRI score. In conclusion, the safety and efficacy of ADSVF and microfat injection in Crohn's disease fistulas were maintained at 3 years, demonstrating that this innovative strategy is effective in producing a long-lasting healing effect. The ongoing multicentre randomized placebo-controlled trial (NCT04010526) will be helpful to define the place for this approach in the current therapeutic arsenal., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
25. Intra-Articular Injection of Autologous Microfat and Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Comparative Study.
- Author
-
Louis ML, Dumonceau RG, Jouve E, Cohen M, Djouri R, Richardet N, Jourdan E, Giraudo L, Dumoulin C, Grimaud F, George FD, Veran J, Sabatier F, and Magalon J
- Subjects
- Humans, Hyaluronic Acid therapeutic use, Injections, Intra-Articular, Treatment Outcome, Osteoarthritis, Knee therapy, Platelet-Rich Plasma
- Abstract
Purpose: To compare a single abdominal microfat (MF) injection mixed or not with platelet-rich plasma (PRP) Low Dose (LD) or High Dose (HD) in order to improve MRI parameters, alleviate pain and enhance functional capacity in knee osteoarthritis., Methods: Patients with symptomatic grade 2 to 4 knee osteoarthritis according to the International Cartilage Repair Society MRI classification were selected. They were prospectively assessed at baseline and at 3 and 6 months of follow-up. The primary endpoint was change in the maximum of value of cartilage relaxation time in T2 mapping sequences (T2max) at 3 months. Secondary endpoints were MRI grade severity and joint space assessment, Western Ontario and McMaster Universities Arthritis Index score, pain evaluation, knee range of motion, and patients' satisfaction. Adverse events were also collected. The complete cell counts and growth factors content of injected products were assessed to analyze their potential relationship with MRI and clinical outcomes., Results: Three groups of 10 patients received a single injection of 10 cc of a mix (1:1) containing MF-Saline, MF-PRP LD or MF-PRP HD. T2max did not change significantly over the time for any of the groups. All treatments significantly improved knee functional status and symptom relief at 3 and 6 months. All patients were responders in the MF/PRP HD at 3 months and significantly higher compared to MF/PRP LD. Half of the injected PRP in the MF/PRP LD group displayed red blood cell contamination of over 8%, which was correlated with an impairment of T2max., Conclusion: A single intra-articular injection of MF with or without PRP is safe and may offer a significant clinical improvement in patients with osteoarthritis., Level of Evidence: 2; randomized double-blind comparative parallel-group trial (RCT No.: NCT04352075)., (Copyright © 2021 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. Inter-center comparison of good manufacturing practices-compliant stromal vascular fraction and proposal for release acceptance criteria: a review of 364 productions.
- Author
-
François P, Rusconi G, Arnaud L, Mariotta L, Giraudo L, Minonzio G, Veran J, Bertrand B, Dumoulin C, Grimaud F, Lyonnet L, Casanova D, Giverne C, Cras A, Magalon G, Dignat-George F, Sabatier F, Magalon J, and Soldati G
- Subjects
- Cell Survival, Retrospective Studies, Stromal Cells, Adipose Tissue, Endothelial Cells
- Abstract
Background: Even though the manufacturing processes of the stromal vascular fraction for clinical use are performed in compliance with the good manufacturing practices applying to advanced therapy medicinal products, specifications related to stromal vascular fraction quality remain poorly defined. We analyzed stromal vascular fraction clinical batches from two independent good manufacturing practices-compliant manufacturing facilities, the Swiss Stem Cell Foundation (SSCF) and Marseille University Hospitals (AP-HM), with the goal of defining appropriate and harmonized release acceptance criteria., Methods: This retrospective analysis reviewed the biological characteristics of 364 batches of clinical-grade stromal vascular fraction. Collected data included cell viability, recovery yield, cell subset distribution of stromal vascular fraction, and microbiological quality., Results: Stromal vascular fraction from SSCF cohort demonstrated a higher viability (89.33% ± 4.30%) and recovery yield (2.54 × 10
5 ± 1.22 × 105 viable nucleated cells (VNCs) per mL of adipose tissue) than stromal vascular fraction from AP-HM (84.20% ± 5.96% and 2.25 × 105 ± 1.11 × 105 VNCs per mL). AP-HM batches were significantly less contaminated (95.71% of sterile batches versus 74.15% for SSCF batches). The cell subset distribution was significantly different (higher proportion of endothelial cells and lower proportion of leukocytes and pericytes in SSCF cohort)., Conclusions: Both centers agreed that a good manufacturing practices-compliant stromal vascular fraction batch should exert a viability equal or superior to 80%, a minimum recovery yield of 1.50 × 105 VNCs per mL of adipose tissue, a proportion of adipose-derived stromal cells at least equal to 20%, and a proportion of leukocytes under 50%. In addition, a multiparameter gating strategy for stromal vascular fraction analysis is proposed.- Published
- 2021
- Full Text
- View/download PDF
27. A Retrospective Analysis of Characteristic Features of Responders and Impaired Patients to a Single Injection of Pure Platelet-Rich Plasma in Knee Osteoarthritis.
- Author
-
Bec C, Rousset A, Brandin T, François P, Rabarimeriarijaona S, Dumoulin C, Heleu G, Grimaud F, Veran J, Magalon G, Dignat-George F, Sabatier F, Louis ML, and Magalon J
- Abstract
(1) Background: The emergence of injectable "biologic" medication creates a new approach to treat osteoarthritis (OA). Among them, the use of intra-articular injection of PRP became widespread despite the absence of consensus regarding its optimal composition. The aim of this study was to retrospectively correlate an extensive biological characterization of injected PRP to the clinical responses of patients presenting knee OA. (2) Methods: This retrospective study included 75 patients with knee OA. Cartilage lesions were assessed using magnetic resonance imaging and the International Cartilage Regeneration Society (ICRS) classification. PRP extensive biological characterization was performed and patients' subjective symptoms were recorded before injection and 3 and 6 months after injection using the Knee injury and Osteoarthritis Outcome Score (KOOS). Responders were defined by an improvement of 10 points on KOOS. (3) Results: At 6 months, 63.0% of the patients were responders. Impairment was characterized by a significantly higher proportion of patients with three compartments altered at baseline MRI and receiving a significantly higher dose of platelets compared to responders. (4) Conclusions: Single injection of pure PRP resulted in significant clinical improvement in the management of knee OA. Both baseline MRI and PRP biological features may be predictive factors of the clinical response, highlighting that a better understanding of action mechanism of PRP is still required.
- Published
- 2021
- Full Text
- View/download PDF
28. Response to Universal Classification System for Platelet-Rich Plasma (PRP): A Method to define the variables in PRP production.
- Author
-
Magalon J, Abellan-Lopez M, Brandin T, Degioanni C, Grimaud F, Veran J, Dignat George F, Bertrand B, and Sabatier F
- Subjects
- Adipose Tissue, Animals, Leukocytes, Mice, Mice, Nude, Burns, Platelet-Rich Plasma
- Published
- 2021
- Full Text
- View/download PDF
29. Technical and biological review of authorized medical devices for platelets-rich plasma preparation in the field of regenerative medicine.
- Author
-
Magalon J, Brandin T, Francois P, Degioanni C, De Maria L, Grimaud F, Veran J, Dignat-George F, and Sabatier F
- Subjects
- Humans, Equipment and Supplies standards, Platelet-Rich Plasma metabolism, Regenerative Medicine methods
- Abstract
Platelet-rich plasma (PRP) has seen increased interest and utilization over the past decade, particularly in the field of musculoskeletal disease. This growth has been accompanied by the development of medical devices to realize PRP preparation which includes blood collection, centrifugation, and PRP isolation. The final PRP composition is directly influenced by this preparation step and absence of biological quality control led to a lack of comparability between PRP products that could explain the large variability in the clinical benefit of PRP reported in literature. To circumvent this issue, the scientific community developed different PRP classifications but none of them have been adopted. The goal of this review is to furnish both technical and biological characteristics from PRP commercial systems. On review of 1379 studies, 105 studies were selected according to inclusion criteria for technical analysis and led to the identification of 50 commercial systems that have been classified in three technical categories based on the blood harvesting technique (tubes, syringes or bags). Twelve studies were selected and sufficiently describe biological characteristics from only 14 commercial systems from the 50 identified in the technical analysis. Inclusion of duplicates characterization from a same PRP system lead to the final analysis of 36 PRP preparations that met the inclusion criteria of the biological analysis. All these PRP preparations have been classified among the seven existing classifications. Comparison from all biological parameters and classifications revealed a large heterogeneity among the available current PRP commercial systems. Index of biological sensitivity of classifications to distinguish PRP preparations were also variable. Although these findings should help clinicians in selecting a system that meets their specific needs, this also raises the question to standardize the parameters to biologically define PRP preparation among users and to systematically performed PRP qualification when used.
- Published
- 2021
- Full Text
- View/download PDF
30. Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods.
- Author
-
François P, Giraudo L, Veran J, Bertrand B, Dumoulin C, Aboudou H, Grimaud F, Vogtensperger M, Velier M, Arnaud L, Lyonnet L, Simoncini S, Guillet B, Dignat-George F, Magalon J, and Sabatier F
- Subjects
- Animals, Automation, Collagenases metabolism, Disease Models, Animal, Female, Humans, Ischemia pathology, Kinetics, Mice, Nude, Neovascularization, Physiologic, Stromal Cells cytology, Substrate Specificity, Adipose Tissue blood supply, Adipose Tissue cytology, Cell Culture Techniques economics, Cell Culture Techniques methods, Cost-Benefit Analysis
- Abstract
The therapeutic use of adipose-derived stromal vascular fraction (SVF) is expanding in multiple pathologies. Various processes have been proposed for manufacturing SVF but they must be revisited based on advanced therapy medicinal product (ATMP) regulations. We report here the development and validation of a fully good manufacturing practices (GMP)-compliant protocol for the isolation of SVF. Adipose tissue was collected from healthy volunteers undergoing lipoaspiration. The optimal conditions of collagenase digestion and washing were determined based on measurements of SVF cell viability, yield recovery, and cell subset distribution. Comparability of the SVF obtained using the newly developed manufacturing process (n = 6) and the Celution-based automated method (n = 33), used as a reference, was established using inter-donor analyses. Characteristics of SVF (n = 5) generated using both manufacturing protocols were analyzed for an intra-donor comparison. In addition, these comparisons also included the determination of colony-forming unit fibroblast frequency, in vitro angiogenic activity, and in vivo regenerative effects in a mouse ischemic cutaneous wound model. We successfully developed a process for the generation of SVF presenting higher cell viability and yield recovery compared to the Celution device-based protocol. Characteristics of the SVF including phenotype, capacity for angiogenesis, and wound-healing promotion attested to the comparability of the two manufacturing processes. We validated an optimized non-automated process that should allow for a GMP-compliant, more affordable, and reduced-cost strategy to exploit the potential of SVF-based regenerative therapies.
- Published
- 2020
- Full Text
- View/download PDF
31. Feasibility of First Injection of Autologous Adipose Tissue-Derived Stromal Vascular Fraction in Human Scarred Vocal Folds: A Nonrandomized Controlled Trial.
- Author
-
Mattei A, Bertrand B, Jouve E, Blaise T, Philandrianos C, Grimaud F, Giraudo L, Aboudou H, Dumoulin C, Arnaud L, Revis J, Galant C, Velier M, Veran J, Dignat-George F, Dessi P, Sabatier F, Magalon J, and Giovanni A
- Subjects
- Adipose Tissue cytology, Adult, Dysphonia pathology, Feasibility Studies, Female, Humans, Injections, Male, Middle Aged, Phonation, Quality of Life, Speech Acoustics, Transplantation, Autologous, Treatment Outcome, Adipose Tissue transplantation, Cicatrix therapy, Dysphonia therapy, Mesenchymal Stem Cell Transplantation adverse effects, Vocal Cords pathology
- Abstract
Importance: Patients with scarred vocal folds, whether congenitally or after phonosurgery, often exhibit dysphonia that negatively affects daily life and is difficult to treat. The autologous adipose tissue-derived stromal vascular fraction (ADSVF) is a readily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties., Objective: To evaluate the feasibility and tolerability of local injections of autologous ADSVF in patients with scarred vocal folds., Design, Setting, and Participants: CELLCORDES (Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction) is a prospective, open-label, single-arm, single-center, nonrandomized controlled trial with a 12-month follow-up and patient enrollment from April 1, 2016, to June 30, 2017. Eight patients with severe dysphonia attributable to vocal fold scarring associated with a congenital malformation or resulting from microsurgical sequelae (voice handicap index score >60 of 120) completed the study. Data analysis was performed from September 1, 2018, to January 1, 2019., Interventions: Injection of ADSVF into 1 or 2 vocal folds., Main Outcomes and Measures: The primary outcomes were feasibility and the number and severity of adverse events associated with ADSVF-based therapy. The secondary outcomes were changes in vocal assessment, videolaryngostroboscopy, self-evaluation of dysphonia, and quality of life at 1, 6, and 12 months after cell therapy., Results: Seven women and 1 man (mean [SD] age, 44.6 [10.4] years) were enrolled in this study. Adverse events associated with liposuction and ADSVF injection occurred; most of them resolved spontaneously. One patient received minor treatment to drain local bruising, and another experienced a minor contour defect at the liposuction site. At 12 months, the voice handicap index score was improved in all patients, with a mean (SD) improvement from baseline of 40.1 (21.5) points. Seven patients (88%) were considered to be responders, defined as improvement by 18 points or more in the voice handicap index score (the minimum clinically important difference)., Conclusions and Relevance: The findings suggest that autologous ADSVF injection in scarred vocal folds is feasible and tolerable. The findings require confirmation in a randomized clinical trial with a larger population., Trial Registration: ClinicalTrials.gov Identifier: NCT02622464.
- Published
- 2020
- Full Text
- View/download PDF
32. Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's Disease.
- Author
-
Le Douce J, Maugard M, Veran J, Matos M, Jégo P, Vigneron PA, Faivre E, Toussay X, Vandenberghe M, Balbastre Y, Piquet J, Guiot E, Tran NT, Taverna M, Marinesco S, Koyanagi A, Furuya S, Gaudin-Guérif M, Goutal S, Ghettas A, Pruvost A, Bemelmans AP, Gaillard MC, Cambon K, Stimmer L, Sazdovitch V, Duyckaerts C, Knott G, Hérard AS, Delzescaux T, Hantraye P, Brouillet E, Cauli B, Oliet SHR, Panatier A, and Bonvento G
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Alzheimer Disease drug therapy, Alzheimer Disease physiopathology, Animals, Astrocytes drug effects, Binding Sites, Brain pathology, Brain physiopathology, Cognitive Dysfunction pathology, Cognitive Dysfunction physiopathology, Energy Metabolism drug effects, Female, Glucose metabolism, Humans, Male, Mice, Transgenic, Middle Aged, Neuronal Plasticity drug effects, Phosphoglycerate Dehydrogenase metabolism, Receptors, N-Methyl-D-Aspartate metabolism, Serine administration & dosage, Serine pharmacology, Serine therapeutic use, Spatial Memory drug effects, Alzheimer Disease metabolism, Alzheimer Disease pathology, Astrocytes metabolism, Cognitive Dysfunction metabolism, Glycolysis drug effects, Serine biosynthesis
- Abstract
Alteration of brain aerobic glycolysis is often observed early in the course of Alzheimer's disease (AD). Whether and how such metabolic dysregulation contributes to both synaptic plasticity and behavioral deficits in AD is not known. Here, we show that the astrocytic l-serine biosynthesis pathway, which branches from glycolysis, is impaired in young AD mice and in AD patients. l-serine is the precursor of d-serine, a co-agonist of synaptic NMDA receptors (NMDARs) required for synaptic plasticity. Accordingly, AD mice display a lower occupancy of the NMDAR co-agonist site as well as synaptic and behavioral deficits. Similar deficits are observed following inactivation of the l-serine synthetic pathway in hippocampal astrocytes, supporting the key role of astrocytic l-serine. Supplementation with l-serine in the diet prevents both synaptic and behavioral deficits in AD mice. Our findings reveal that astrocytic glycolysis controls cognitive functions and suggest oral l-serine as a ready-to-use therapy for AD., Competing Interests: Declaration of Interests The authors declare no competing interests., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
33. A retrospective analysis of characteristic features of responder patients to autologous serum eye drops in routine care.
- Author
-
Levy N, Wang Yin GH, Noharet R, Ghazouane R, Grimaud F, Aboudou H, Darque A, Delmotte N, Veran J, Hoffart L, Denis D, Sabatier F, and Magalon J
- Subjects
- Dry Eye Syndromes metabolism, Female, Humans, Male, Middle Aged, Ophthalmic Solutions, Retrospective Studies, Treatment Outcome, Dry Eye Syndromes therapy, Serum, Tears metabolism
- Abstract
Purpose: Autologous serum eye drops (ASEDs) are used worldwide to treat dry eye disease (DED). However, the biological composition of ASEDs has not been well investigated, and effectiveness predictive factors remain to be identified. The main objective of this study was to compare the response of patients treated with ASEDs biologically characterized and used for DED routine care., Methods: This retrospective observational study was conducted in a single university hospital, and included 50 patients (87 eyes) with DED refractory to conventional treatment and resulting from various etiologies with Ocular Surface Disease Index (OSDI) ≥ 20. Each patient used eight drops a day per treated eye with 20% diluted ASEDs. Undiluted serum extensive biological characterizations were performed, and symptoms were recorded before the initiation of ASEDs and closer to the sixth month of treatment. Responders were defined as presenting an improvement from baseline ≥14 points in OSDI and/or ≥1 grade in corneal fluorescence staining for all eyes treated., Results: The OSDI and the Oxford scale were significantly reduced from 68.7 ± 23.2 to 54.8 ± 25.7 and 3.2 ± 1.5 to 2.1 ± 1.3 (p ≤ 0.0001), respectively. A total of 68% of the patients were responders. Nonresponding patients had significantly higher epidermal growth factor concentrations in the serum compared to responders (p = 0.017)., Conclusions: ASED administration resulted in significant clinical improvement in the management of DED. Biological differences observed between responders and nonresponders suggested that a better understanding of the biological activity of ASEDs is still required., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
34. Allogenic Pure Platelet-Rich Plasma Therapy for Rotator Cuff Disease: A Bench and Bed Study: Letter to the Editor.
- Author
-
Magalon J, Velier M, Vogtensperger M, Veran J, Grimaud F, and Sabatier F
- Subjects
- Humans, Rotator Cuff, Platelet-Rich Plasma, Rotator Cuff Injuries
- Published
- 2019
- Full Text
- View/download PDF
35. Development of Autologous Platelet-Rich Plasma Mixed-Microfat as an Advanced Therapy Medicinal Product for Intra-Articular Injection of Radio-Carpal Osteoarthritis: From Validation Data to Preliminary Clinical Results.
- Author
-
Mayoly A, Iniesta A, Curvale C, Kachouh N, Jaloux C, Eraud J, Vogtensperger M, Veran J, Grimaud F, Jouve E, Casanova D, Sabatier F, Legré R, and Magalon J
- Subjects
- Adolescent, Adult, Aged, Cells, Cultured, Chondrocytes cytology, Female, Humans, Male, Mesenchymal Stem Cell Transplantation adverse effects, Mesenchymal Stem Cells cytology, Middle Aged, Platelet Transfusion adverse effects, Platelet-Rich Plasma cytology, Adipose Tissue cytology, Carpal Joints pathology, Mesenchymal Stem Cell Transplantation methods, Osteoarthritis therapy, Platelet Transfusion methods
- Abstract
Wrist osteoarthritis (OA) is one of the most common conditions encountered by hand surgeons with limited efficacy of non-surgical treatments. The purpose of this study is to describe the Platelet-Rich Plasma (PRP) mixed-microfat biological characteristics of an experimental Advanced Therapy Medicinal Product (ATMP) needed for clinical trial authorization and describe the clinical results obtained from our first three patients 12 months after treatment (NCT03164122). Biological characterization of microfat, PRP and mixture were analysed in vitro according to validated methods. Patients with stage four OA according to the Kellgren Lawrence classification, with failure to conservative treatment and a persistent daily painful condition >40 mm according to the visual analog scale (VAS) were treated. Microfat-PRP ATMP is a product with high platelet purity, conserved viability of stromal vascular fraction cells, chondrogenic differentiation capacity in vitro and high secretion of IL-1Ra anti-inflammatory cytokine. For patients, the only side effect was pain at the adipose tissue harvesting sites. Potential efficacy was observed with a pain decrease of over 50% (per VAS score) and the achievement of minimal clinically important differences for DASH and PRWE functional scores at one year in all three patients. Microfat-PRP ATMP presented a good safety profile after an injection in wrist OA. Efficacy trials are necessary to assess whether this innovative strategy could delay the necessity to perform non-conservative surgery.
- Published
- 2019
- Full Text
- View/download PDF
36. Use of platelet-rich plasma in regenerative medicine: technical tools for correct quality control.
- Author
-
Graiet H, Lokchine A, Francois P, Velier M, Grimaud F, Loyens M, Berda-Haddad Y, Veran J, Dignat-George F, Sabatier F, and Magalon J
- Abstract
Background/aims: Platelet-rich plasma (PRP) injections are used in sports medicine and have been the subject of increased clinical interest. However, there have been very few reports of the composition of initial whole blood and the final PRP product. The objective of this study was to provide technical tools to perform a correct characterisation of platelets, leucocytes and red blood cells (RBCs) from whole blood and PRP., Methods: Blood and PRP were obtained from 26 healthy volunteers and prepared according to the varying parameters encountered within PRP process preparation and quantification (harvesting method, anticoagulant used, sampling method, counting method). Concentrations were measured at t=0, t=1, t=6 and t=24 hours., Results: Sampling of blood in Eppendorf tubes significantly decreased platelet concentration over time, whereas sampling in Microvette EDTA-coated tube kept platelet concentration stable until 24 hours. A non-significant difference was observed in platelet counts in PRP with impedance (median (IQR): 521.8 G/L (505.3-524.7)) and fluorescence (591.5 G/L (581.5-595.8)) methods. Other studied parameters did not influence platelet concentrations in blood or PRP samples. Leucocytes and RBC counts were similar whatever the anticoagulant, sampling, harvesting and counting methods used for both blood and PRP samples., Conclusions: Systematic sampling of blood and PRP in EDTA-coated tubes for quality control is recommended. The use of a validated counter for PRP sample should also be taken into account., Competing Interests: Competing interests: None declared.
- Published
- 2018
- Full Text
- View/download PDF
37. Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer's disease.
- Author
-
Ceyzériat K, Ben Haim L, Denizot A, Pommier D, Matos M, Guillemaud O, Palomares MA, Abjean L, Petit F, Gipchtein P, Gaillard MC, Guillermier M, Bernier S, Gaudin M, Aurégan G, Joséphine C, Déchamps N, Veran J, Langlais V, Cambon K, Bemelmans AP, Baijer J, Bonvento G, Dhenain M, Deleuze JF, Oliet SHR, Brouillet E, Hantraye P, Carrillo-de Sauvage MA, Olaso R, Panatier A, and Escartin C
- Subjects
- Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor genetics, Amyloid beta-Protein Precursor metabolism, Animals, Apolipoproteins E metabolism, Aspartic Acid Endopeptidases metabolism, Astrocytes metabolism, Disease Models, Animal, Excitatory Postsynaptic Potentials drug effects, Excitatory Postsynaptic Potentials genetics, Extracellular Signal-Regulated MAP Kinases metabolism, Glial Fibrillary Acidic Protein metabolism, Hippocampus cytology, Janus Kinase 2 genetics, Janus Kinase 2 metabolism, Male, Maze Learning drug effects, Mice, Mice, Transgenic, Mutation genetics, Presenilin-1 genetics, Presenilin-1 metabolism, STAT1 Transcription Factor metabolism, Suppressor of Cytokine Signaling 3 Protein genetics, Suppressor of Cytokine Signaling 3 Protein metabolism, Alzheimer Disease pathology, Alzheimer Disease physiopathology, Astrocytes pathology
- Abstract
Astrocyte reactivity and neuroinflammation are hallmarks of CNS pathological conditions such as Alzheimer's disease. However, the specific role of reactive astrocytes is still debated. This controversy may stem from the fact that most strategies used to modulate astrocyte reactivity and explore its contribution to disease outcomes have only limited specificity. Moreover, reactive astrocytes are now emerging as heterogeneous cells and all types of astrocyte reactivity may not be controlled efficiently by such strategies.Here, we used cell type-specific approaches in vivo and identified the JAK2-STAT3 pathway, as necessary and sufficient for the induction and maintenance of astrocyte reactivity. Modulation of this cascade by viral gene transfer in mouse astrocytes efficiently controlled several morphological and molecular features of reactivity. Inhibition of this pathway in mouse models of Alzheimer's disease improved three key pathological hallmarks by reducing amyloid deposition, improving spatial learning and restoring synaptic deficits.In conclusion, the JAK2-STAT3 cascade operates as a master regulator of astrocyte reactivity in vivo. Its inhibition offers new therapeutic opportunities for Alzheimer's disease.
- Published
- 2018
- Full Text
- View/download PDF
38. Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.
- Author
-
Mattei A, Magalon J, Bertrand B, Grimaud F, Revis J, Velier M, Veran J, Dessi P, Sabatier F, and Giovanni A
- Subjects
- Adult, Female, Humans, Adipose Tissue metabolism, Vocal Cords physiopathology
- Published
- 2018
- Full Text
- View/download PDF
39. Growth Factors Levels Determine Efficacy of Platelets Rich Plasma Injection in Knee Osteoarthritis: A Randomized Double Blind Noninferiority Trial Compared With Viscosupplementation.
- Author
-
Louis ML, Magalon J, Jouve E, Bornet CE, Mattei JC, Chagnaud C, Rochwerger A, Veran J, and Sabatier F
- Subjects
- Adult, Aged, Double-Blind Method, Female, Humans, Hyaluronic Acid administration & dosage, Hyaluronic Acid therapeutic use, Injections, Intra-Articular, Male, Middle Aged, Pain Management, Pain Measurement methods, Patient Satisfaction, Platelet-Derived Growth Factor analysis, Severity of Illness Index, Transforming Growth Factor beta1 blood, Treatment Outcome, Vascular Endothelial Growth Factor A blood, Young Adult, Growth Substances blood, Osteoarthritis, Knee therapy, Platelet Transfusion methods, Platelet-Rich Plasma chemistry, Viscosupplementation methods
- Abstract
Purpose: To assess the noninferiority of a single platelet-rich plasma (PRP) injection compared with hyaluronic acid (HA), to alleviate pain and enhance functional capacity in knee osteoarthritis, and identify biological characteristics of PRP that may affect their efficacy., Methods: Fifty-four patients with symptomatic knee osteoarthritis received a single injection of either PRP (26 patients) or HA (28 patients). They were assessed at baseline and at 1, 3, and 6 months. The primary endpoint was the change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) score at 3 months, and secondary endpoints were responders' rate (improvement of at least 5 points or 40% of WOMAC total score at 3 months) of pain evaluation and patient's subjective satisfaction. Cell counts and the contents of vascular endothelial growth factor (VEGF), platelet-derived growth factor-AB (PDGF-AB), transforming growth factor beta 1 (TGF-β1) content of injected PRP were assessed to analyze their relationship with clinical outcome., Results: Both treatments proved their improvement in knee functional status and symptom relief, with a significant decrease observed at 1 month on all scores except for pain VAS in PRP group and WOMAC function score in the HA group. No difference between groups regarding WOMAC and VAS scores was observed. A higher percentage of responders was observed in the PRP group (72.7%) than in the HA group (45.8%) without significance (P = .064). The quantity of injected PDGF-AB and TGF-β1 correlated with the change in WOMAC scores at 3 months and was lower in responders than in nonresponders (P = .009 and P = .003, respectively)., Conclusions: Current results indicated that a single injection of very pure PRP offers a significant clinical improvement in the management of knee osteoarthritis, equivalent to a single HA injection in this patient population. Moreover, a significant correlation between the doses of TGF-β1 and PDGF-AB and the worsening of WOMAC score 3 months after the procedure was found., Level of Evidence: Level II, randomized double blind controlled trial., (Copyright © 2017 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
40. [Autologous serum tears: Long-term treatment in dry eye syndrome].
- Author
-
Beylerian M, Lazaro M, Magalon J, Veran J, Darque A, Grimaud F, Stolowy N, Beylerian H, Sabatier F, and Hoffart L
- Subjects
- Adult, Aged, Aged, 80 and over, Dry Eye Syndromes etiology, Female, Fluorescein, Follow-Up Studies, Graft vs Host Disease complications, Humans, Lubricant Eye Drops isolation & purification, Male, Middle Aged, Preservation, Biological, Retrospective Studies, Severity of Illness Index, Sjogren's Syndrome complications, Surface Tension, Tears chemistry, Tears metabolism, Dry Eye Syndromes drug therapy, Lubricant Eye Drops therapeutic use, Serum
- Abstract
Introduction: Dry eye disease is a multifactorial pathology of the ocular surface. The high incidence of this pathology, as well as its significant impact on quality of life and vision and its financial cost, makes it a real public health problem. While the treatment of mild cases is generally simple and effective, treatment of severe forms is often disappointing. The use of autologous serum tears (AST) represents a therapeutic alternative for the most severe cases. The purpose of our study is to evaluate the efficacy of long-term AST treatment in patients with severe dry eye disease refractory to conventional treatment or secondary to systemic diseases such as Sjögren's syndrome or Graft versus Host disease (GVH), or ocular pathologies such as neurotrophic keratitis, chemical burns and ocular cicatricial pemphigoid., Patients and Methods: This is a monocentric retrospective observational study conducted on 47 patients, with 83 eyes treated with autologous serum eye drops for isolated or secondary dry eye disease at the Marseille Public Hospitals between April 2014 and April 2017. The patients' subjective symptoms (ocular surface disease index [OSDI] score), their degree of satisfaction and the side effects were collected using questionnaires. Tear Break Up Time (BUT) and Schirmer scores were noted. A clinical evaluation based on fluorescein staining (Oxford score) was carried out prior to treatment with AST at P0 followed by 5 periods: P1 (between 1 and 3 months), P2 (3 to 9 months), P3 (9 to 15 months), P4 (15 months to 24 months), and P5 (>24 months)., Results: Out of the 83 eyes treated, the mean age was 54.39±21.56. There were 20 males (42.55 %) and 27 females (57.44 %); treatment indications consisted mainly of 25.53 % GVH, 21.27 % severe dry eye disease and 19.14 % Sjögren syndrome. The mean duration of follow-up was 9.82 months±15.50. The OSDI score decreased by 19.32 points±29.37 (P<0.05) between P0 and P1 and by 23.06 points±18.41 (P<0.05) between P0 and P4. The Oxford clinical score showed a significant decrease by the third month of treatment, between P0 and P2, by 1.32 points±1.76 (P<0.05). The Schirmer test and the BUT also showed an improvement in dry eye symptoms over time with AST, significantly at P1 (P<0.05)., Discussion: Complementary biological analyzes on the composition of AST are under way in order to identify predictive factors of effectiveness; patients not responding to AST treatment might respond to allogeneic serum from healthy donor cord blood., Conclusion: On this first series of 83 eyes treated with ASD, clinical efficacy was noted in most of the patients. No infectious complications were reported, and the satisfaction rate was very high., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
41. [Treatment of wrinkles of the upper lip by emulsified fat or "Nanofat": Biological and clinical study about 4 cases].
- Author
-
Mesguich Batel F, Bertrand B, Magalon J, François P, Velier M, Veran J, Mallet S, Jouve E, Sabatier F, and Casanova D
- Subjects
- Female, Humans, Injections, Intradermal methods, Middle Aged, Photography methods, Treatment Outcome, Adipose Tissue transplantation, Lip, Patient Satisfaction, Rejuvenation, Rhytidoplasty methods, Skin Aging drug effects
- Abstract
Objective: Emulsified fat injection showed its interest in aesthetic facial surgery. The adipose tissue harvested is mechanically emulsified and filtered. The suspension obtained is injected into the dermis through small diameter needles (27 to 30 gauges). The objective of our study was to evaluate the biological composition of emulsified fat and its clinical effectiveness in the treatment of peri-oral wrinkles in 4 patients aged 50 to 59 years., Material and Method: Each patient received an intradermal injection of emulsified fat in the peri-oral wrinkles prepared from abdominal fat under local anesthesia. The cell viability, stromal vascular fraction (FVS) composition in emulsified fat and the adipocyte differentiation capacity of mesenchymal stem cells (MSC) were studied. The clinical results were evaluated by standardized photographs, 3D microphotography, confocal microscopy, and self-evaluation of patient satisfaction over a period of 4 months., Results: The biological study of the emulsified fat found a lysis of all the adipocytes. The mean number of FVS cells was 126,330±2758 cells by cc of emulsified fat with preserved cell viability (85.1±6.84 %) and a good proportion of regeneratives cells (18.77±6.2 %). The clinical study found a tendency to decrease the volume of wrinkles on standardized photography and 3D microphotography no significative. Patients were satisfied with treatment with an average score of 7±1.15/10 to 4 months., Conclusion: Intradermal injection of emulsified fat seems to be an interesting treatment of face wrinkles. Our study has shown its safety, but additional studies seems necessary to confirm its clinical efficacy., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
42. Cell therapy and vocal fold scarring.
- Author
-
Mattei A, Magalon J, Bertrand B, Philandrianos C, Veran J, and Giovanni A
- Subjects
- Animals, Cicatrix etiology, Dysphonia etiology, Dysphonia surgery, Humans, In Vitro Techniques, Models, Animal, Treatment Outcome, Adipocytes cytology, Cell- and Tissue-Based Therapy methods, Cicatrix surgery, Mesenchymal Stem Cell Transplantation methods, Mesenchymal Stem Cells cytology, Vocal Cords pathology, Vocal Cords surgery
- Abstract
Vocal fold microstructure is complex and can be affected by laryngeal microsurgery, inducing scarring that prevents mechanical uncoupling of epithelium and muscle, leading to vibration disorder and disabling dysphonia. Treatment options presently are few, and often without efficacy for vibration, having only an impact on volume to reduce glottal closure defect. The present review of the literature had two aims: (i) to report the current state of the literature on cell therapy in vocal fold scarring; and (ii) to analyze the therapeutic interest of the adipose-derived stromal vascular fraction in the existing therapeutic armamentarium. A PubMed
® search conducted in September 2016 retrieved English or French-language original articles on the use of stem cells to treat vocal fold scarring. Twenty-seven articles published between 2003 and 2016 met the study selection criteria. Mesenchymal stem cells were most widely used, mainly derived from bone marrow or adipose tissue. Four studies were performed in vitro on fibroblasts, and 18 in vivo on animals. End-points comprised: (i) scar analysis (macro- and micro-scopic morphology, viscoelastic properties, extracellular matrix, fibroblasts); and (ii) assessment of stem cell survival and differentiation. The studies testified to the benefit of mesenchymal stem cells, and especially those of adipose derivation. The stromal vascular fraction exhibits properties that might improve results by facilitating production logistics., (Copyright © 2017. Published by Elsevier Masson SAS.)- Published
- 2017
- Full Text
- View/download PDF
43. What About the Rheological Properties of PRP/Microfat Mixtures in Fat Grafting Procedure?
- Author
-
Ghazouane R, Bertrand B, Philandrianos C, Veran J, Abellan M, Francois P, Velier M, Orneto C, Piccerelle P, and Magalon J
- Subjects
- Cosmetic Techniques, Esthetics, Female, Graft Rejection, Graft Survival, Humans, Hyaluronic Acid administration & dosage, Tissue and Organ Harvesting methods, Adipose Tissue transplantation, Platelet-Rich Plasma, Rejuvenation physiology, Rheology methods, Surgery, Plastic methods
- Abstract
Background: Fat grafting has emerged as a reference procedure in daily plastic surgery practice. Unpredictable fat resorption is the main clinical problem. For this purpose, the addition of PRP to enhance fat revascularization is now an easy and popular procedure. However, no consensus exists regarding the respective volume of fat and PRP used to obtain the ideal mixture. This study investigated the rheological properties of microfat mixed with different proportions of PRP. Results obtained were compared with commercialized hyaluronic acid fillers., Methods: Microfat and PRP preparations were performed using standardized techniques. Lipoaspirate residue and blood were obtained from six patients undergoing aesthetic facial microlipofilling. Elastic modulus G' and tan δ (proportion of elasticity versus fluidity) were obtained for the following conditions: microfat alone and microfat mixed with 10, 30 or 50% of PRP., Results: An expected decrease in elastic modulus was observed by adding increase volumes of PRP. Two groups of products with different rheological properties were considered based on statistical differences highlighted regarding the value of G'. Mean tan δ varied from 0.20 ± 0.04 (microfat alone) to 0.28 ± 0.08 (50% microfat/50% PRP). Microfat mixed with 10% of PRP presents consistency comparable to stiffer fillers, whereas microfat mixed with 30 or 50% corresponds to softer fillers., Conclusion: Rheological differences were highlighted given the proportion of PRP added to the microfat. Further studies assessing the impact of increased doses of platelets in microfat/PRP mixtures on clinical outcomes should also be investigated. Our findings will help clinicians to choose a mixture that meets their specific needs for a given indication., No Level Assigned: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- Published
- 2017
- Full Text
- View/download PDF
44. Comment on "Responders to Platelet-Rich Plasma in Osteoarthritis: A Technical Analysis".
- Author
-
Magalon J, Velier M, Francois P, Graiet H, Veran J, and Sabatier F
- Subjects
- Humans, Injections, Intra-Articular, Osteoarthritis, Knee blood, Osteoarthritis, Platelet-Rich Plasma
- Published
- 2017
- Full Text
- View/download PDF
45. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients.
- Author
-
Daumas A, Magalon J, Jouve E, Truillet R, Casanova D, Giraudo L, Veran J, Benyamine A, Dignat-George F, Magalon G, Sabatier F, and Granel B
- Subjects
- Adult, Aged, Cell Fractionation, Endothelial Cells cytology, Endothelial Cells transplantation, Female, Follow-Up Studies, Hand, Humans, Injections, Subcutaneous, Middle Aged, Patient Reported Outcome Measures, Raynaud Disease etiology, Scleroderma, Systemic complications, Skin Ulcer etiology, Skin Ulcer therapy, Transplantation, Autologous, Treatment Outcome, Adipose Tissue cytology, Fingers pathology, Raynaud Disease therapy, Scleroderma, Systemic therapy, Stromal Cells transplantation
- Abstract
Introduction: Hand involvement confers a substantial handicap in work and daily activities in patients with Systemic sclerosis (SSc). Autologous adipose-derived stromal vascular fraction is as an easily accessible source of cells with regenerative effects. We previously performed a phase I open-label clinical trial (NTC01813279) assessing the safety of subcutaneous injection of autologous adipose-derived stromal vascular fraction. Six and 12-month data have been reported. As patients were followed in our medical centre, we report their longer-term outcome beyond the end of the trial., Patients and Method: Twelve females, mean age 54.5±10.3 years, initially enrolled in the clinical trial were assessed during a scheduled medical care, which took place between 22 and 30months after treatment., Results: Multiple patient-reported outcomes showed sustained improvement, in comparison with the assessment performed just before surgery: 62.5% in the Cochin Hand Function Scale, 51.1% in the Scleroderma Health Assessment Questionnaire, 33.1% in hand pain, and 88.3% in the Raynaud Condition Score. A decrease in the number of digital ulcers number was noted. Mobility, strength and fibrosis of the hand also showed improvement. None of the 8 patients who had previously received iloprost infusion required new infusion., Conclusion: Despite the limits of an open label study, the data are in favour of the long-term safety of the adipose-derived stromal vascular fraction injection. Two randomized double blind, placebo-controlled trials of this therapeutic agent are ongoing in the USA (NCT02396238) and in France (NCT02558543) and will help determine the place of this innovative therapy for SSc patients., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. Adipose Stem Cells Isolated from Excised Burned Tissue: Is There Potential for Clinical Use?
- Author
-
Bertrand B, Magalon J, Veran J, Philandrianos C, and Sabatier F
- Subjects
- Cell Differentiation, Cells, Cultured, Humans, Mesenchymal Stem Cells, Stem Cells, Adipocytes, Adipose Tissue
- Published
- 2017
- Full Text
- View/download PDF
47. Combined use of platelet rich plasma & micro-fat in sport and race horses with degenerative joint disease: preliminary clinical study in eight horses.
- Author
-
Bembo F, Eraud J, Philandrianos C, Bertrand B, Silvestre A, Veran J, Sabatier F, Magalon G, and Magalon J
- Abstract
Background: To assess the safety and potential efficacy of a standardized technique consisting of intra-articular injection of 10 cc of a homogeneous mixed product using autologous micro-fat and platelet rich plasma (PRP) (ratio 1:1) in the carpus or the fetlock joint of sport horses presenting degenerative joint disease (DJD)., Methods: Eight sport horses with DJD confirmed by radiography and ultrasonography and causing lameness and the impossibility to compete were treated. PRP was prepared after a double centrifugation whereas micro-fat was harvested and purified using a closed system. The two products were connected and mixed by gentle back and forth shaking of the syringes to finally obtain 10 ml of an homogeneous mixed product. Follow up was performed from 5 to 10 months with assessment of AAEP lameness score and return to training and competition., Results: Nine joints were treated with significant improvement of the AAEP lameness score three months after the procedure (p = 0.021). Four horses returned to official competition between 5 to 10 months after the procedure (7.0±2.5) and three of them resumed intensive training between 5 to 9 months (6.3±2.3). No adverse event occurred., Conclusion: This study is a first step in the development of innovative therapy for DJD which combines the potential chondrogenic differentiation of MSCs inside equine adipose tissue with the proliferative effect of growth factors present in PRP.
- Published
- 2016
- Full Text
- View/download PDF
48. Histological and Urodynamic Effects of Autologous Stromal Vascular Fraction Extracted from Fat Tissue with Minimal Ex Vivo Manipulation in a Porcine Model of Intrinsic Sphincter Deficiency.
- Author
-
Boissier R, Magalon J, Sabatier F, Veran J, Giraudo L, Giusiano S, Garcia S, Dignat-George F, Arnaud L, Magalon G, Lechevallier E, Berdah S, and Karsenty G
- Subjects
- Animals, Disease Models, Animal, Swine, Urethra pathology, Urinary Incontinence, Stress physiopathology, Adipose Tissue cytology, Stem Cell Transplantation methods, Urethra physiopathology, Urinary Incontinence, Stress surgery, Urodynamics physiology
- Abstract
Purpose: To evaluate the healing abilities of autologous stem cell therapy (stromal vascular fraction) prepared from adipose tissue we used an automated system without an ex vivo culture phase in a pig model of intrinsic sphincteric deficiency., Materials and Methods: A total of 15 pigs underwent endoscopic section of the urethral sphincter. Animals were then randomly assigned to 3 groups, including 1) controls without stromal vascular fraction injection, 2) early injection with stromal vascular fraction 2 to 3 days after section and 3) late stromal vascular fraction injection delivery 30 days after injury. Extraction and stromal vascular fraction injection were performed as a single procedure. The stromal vascular fraction was characterized by flow cytometry. Mesenchymal stem cell-like cells were enumerated by clonogenicity (cfu fibroblast) assay. Study end points included histological assessment of the urethral injury surface and urodynamics to determine maximum urethral pressure., Results: Flow cytometry analysis revealed a mesenchymal stem cell-like phenotype in a mean ± SD of 47.3% ± 11.8% of stromal vascular fraction cells. The cfu fibroblast frequency was 1.3 to 6.6/100 stromal vascular fraction cells (1.3% to 6.6%). Stromal vascular fraction injection was associated with a reduction of the urethral injury surface in the early and late injection groups compared with the respective controls (7% vs 17% and 1% vs 13%, p = 0.050 and 0.029, respectively). On day 30 after injection maximum urethral pressure was significantly higher in the injected groups than in the control group, that is 64% vs 50% of maximum urethral pressure on day 0 (p = 0.04)., Conclusions: These data demonstrate the ability of an autologous stromal vascular fraction to improve the urethral healing process in a large animal model of intrinsic sphincteric deficiency., (Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
49. Efficacy of Autologous Microfat Graft on Facial Handicap in Systemic Sclerosis Patients.
- Author
-
Sautereau N, Daumas A, Truillet R, Jouve E, Magalon J, Veran J, Casanova D, Frances Y, Magalon G, and Granel B
- Abstract
Background: Autologous adipose tissue injection is used in plastic surgery for correction of localized tissue atrophy and has also been successfully offered for treatment of localized scleroderma. We aimed to evaluate whether patients with systemic sclerosis (SSc) and facial handicap could also benefit from this therapy., Methods: We included 14 patients (mean age of 53.8 ± 9.6 years) suffering from SSc with facial handicap defined by Mouth Handicap in Systemic Sclerosis Scale (MHISS) score more than or equal to 20, a Rodnan skin score on the face more than or equal to 1, and maximal mouth opening of less than 55 mm. Autologous adipose tissue injection was performed under local anesthesia using the technique of subcutaneous microinjection. The main objective of this study was an improvement of the MHISS score 6 months after the surgical treatment., Results: The procedure was well tolerated. We observed a mean decrease in the MHISS score of 10.7 points (±5.1; P < 0.0001) at 6 months (35% improvement). Secondary efficacy parameters assessing perioral skin sclerosis, maximum mouth opening, sicca syndrome, and facial pain significantly improved at 3 and 6 months postsurgery. At a 6-month follow-up, 75% of patients were satisfied or very satisfied of the adipose tissue microinjection therapy., Conclusions: Our study suggests that subcutaneous perioral microfat injection in patients with SSc is beneficial in the treatment of facial handicap, skin sclerosis, mouth opening limitation, sicca syndrome, and facial pain. Thus, this minimally invasive approach offers a new hope for face therapy for patients with SSc.
- Published
- 2016
- Full Text
- View/download PDF
50. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices.
- Author
-
Magalon J, Chateau AL, Bertrand B, Louis ML, Silvestre A, Giraudo L, Veran J, and Sabatier F
- Abstract
Background/aim: Significant biological differences in platelet-rich plasma (PRP) preparations have been highlighted and could explain the large variability in the clinical benefit of PRP reported in the literature. The scientific community now recommends the use of classification for PRP injection; however, these classifications are focused on platelet and leucocyte concentrations. This presents the disadvantages of (1) not taking into account the final volume of the preparation; (2) omitting the presence of red blood cells in PRP and (3) not assessing the efficiency of production., Methods: On the basis of standards classically used in the Cell Therapy field, we propose the DEPA (Dose of injected platelets, Efficiency of production, Purity of the PRP, Activation of the PRP) classification to extend the characterisation of the injected PRP preparation. We retrospectively applied this classification on 20 PRP preparations for which biological characteristics were available in the literature., Results: Dose of injected platelets varies from 0.21 to 5.43 billion, corresponding to a 25-fold increase. Only a Magellan device was able to obtain an A score for this parameter. Assessments of the efficiency of production reveal that no device is able to recover more than 90% of platelets from the blood. Purity of the preparation reveals that a majority of the preparations are contaminated by red blood cells as only three devices reach an A score for this parameter, corresponding to a percentage of platelets compared with red blood cells and leucocytes over 90%., Conclusions: These findings should provide significant help to clinicians in selecting a system that meets their specific needs for a given indication.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.